Literature DB >> 12881399

A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland.

L D Locati, P Quattrone, P Bossi, A V Marchianò, G Cantù, L Licitra.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12881399     DOI： 10.1093/annonc/mdg331

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  14 in total

1.  Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer.

Authors:  Martin G Dalin; Alexis Desrichard; Nora Katabi; Vladimir Makarov; Logan A Walsh; Ken-Wing Lee; Qingguo Wang; Joshua Armenia; Lyndsay West; Snjezana Dogan; Lu Wang; Deepa Ramaswami; Alan L Ho; Ian Ganly; David B Solit; Michael F Berger; Nikolaus D Schultz; Jorge S Reis-Filho; Timothy A Chan; Luc G T Morris
Journal:  Clin Cancer Res       Date:  2016-04-21       Impact factor: 12.531

2.  Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications.

Authors:  Yoshitsugu Mitani; Pulivarthi H Rao; Sankar N Maity; Yu-Chen Lee; Renata Ferrarotto; Julian C Post; Lisa Licitra; Scott M Lippman; Merrill S Kies; Randal S Weber; Carlos Caulin; Sue-Hwa Lin; Adel K El-Naggar
Journal:  Clin Cancer Res       Date:  2014-10-14       Impact factor: 12.531

3.  Management and outcome of salivary duct carcinoma in major salivary glands.

Authors:  Elina Salovaara; Olli Hakala; Leif Bäck; Petri Koivunen; Kauko Saarilahti; Fabricio Passador-Santos; Ilmo Leivo; Antti A Mäkitie
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-03-22       Impact factor: 2.503

4.  Salivary gland cancers: biology and molecular targets for therapy.

Authors:  Diana Bell; Ehab Y Hanna
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

5.  Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy.

Authors:  Laura D Locati; Federica Perrone; Barbara Cortelazzi; Martina Imbimbo; Paolo Bossi; Paolo Potepan; Enrico Civelli; Gaetana Rinaldi; Pasquale Quattrone; Lisa Licitra; Silvana Pilotti
Journal:  Cancer Biol Ther       Date:  2014-03-11       Impact factor: 4.742

6.  Expression of Hormone Receptors and HER-2 in Benign and Malignant Salivary Gland Tumors.

Authors:  Nhu Thuy Can; Mark W Lingen; Heather Mashek; James McElherne; Renee Briese; Carrie Fitzpatrick; Annemieke van Zante; Nicole A Cipriani
Journal:  Head Neck Pathol       Date:  2017-07-05

7.  Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma.

Authors:  Tatsuo Masubuchi; Yuichiro Tada; Shin-ichiro Maruya; Yoshiyuki Osamura; Shin-etsu Kamata; Kouki Miura; Chihiro Fushimi; Hideaki Takahashi; Daisuke Kawakita; Seiji Kishimoto; Toshitaka Nagao
Journal:  Int J Clin Oncol       Date:  2014-02-20       Impact factor: 3.402

Review 8.  Systemic therapy in the management of metastatic or advanced salivary gland cancers.

Authors:  Aymen Lagha; Nesrine Chraiet; Mouna Ayadi; Sarra Krimi; Bassem Allani; Hela Rifi; Henda Raies; Amel Mezlini
Journal:  Head Neck Oncol       Date:  2012-05-04

Review 9.  Biological roles and clinical significance of estrogen and androgen receptors in head and neck cancers.

Authors:  Chunhong Qin; Yan Lu; Huimin Zhang; Zhe Zhang; Wei Xu; Shuxin Wen; Wei Gao; Yongyan Wu
Journal:  J Cancer       Date:  2022-04-04       Impact factor: 4.478

10.  Androgen Deprivation Therapy for Patients with Androgen-Receptor-Positive Metastatic Salivary Duct Carcinoma: A Case Report and Review of the Literature.

Authors:  Yongfei You; Panpan Wang; Xi Wan; Liping Xu; Yi Gong; Weihua Zhang
Journal:  Onco Targets Ther       Date:  2021-05-28       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.